Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 May 12;120(10):1530-1532.
doi: 10.1161/CIRCRESAHA.117.310954.

Immunomodulation Is the Key to Cardiac Repair

Tariq Hamid  1 , Sumanth D Prabhu  2
Affiliations
Editorial

Immunomodulation Is the Key to Cardiac Repair

Tariq Hamid et al. Circ Res. .
No abstract available

Keywords: Editorials; cell therapy; immunomodulation; inflammation; mesenchymal stem cells; myocardial infarction.

PubMed Disclaimer

Figures

Figure
Figure
Potential mechanisms underlying the reparative effects of mesenchymal stem cells (MSCs), with the implications of new findings elucidated by the study of Luger et al in blue. MSCs are thought to induce repair predominantly by the secretion of paracrine factors (including those clustered in exosomes) that induce a variety of local effects including the modulation of inflammation, activation of endogenous repair mechanisms, and vascular growth. As cell engraftment rates have been generally been reported to be low, MSC differentiation into cardiomyocytes and other cell types (e.g., endothelial cells [ECs] and vascular smooth muscle cells [VSMCs]) is thought to play a more minor role (dashed arrows). Intravenous delivery of MSCs results in a global distribution of cells that includes the heart, but with the majority of MSCs residing in organs aside from the myocardium. Through as-of-yet poorly defined mechanisms, this produces systemic (and local) immunomodulation and anti-inflammatory responses that in turn augment cardiac repair. Primary targeting of specific pro-inflammatory immune cell subsets, either as an adjunct to MSC therapy or as a stand-alone approach, may further augment systemic anti-inflammatory effects and subsequent cardiac repair.
See this image and copyright information in PMC

Comment on

References

    1. Nguyen PK, Rhee JW, Wu JC. Adult stem cell therapy and heart failure, 2000 to 2016: A systematic review. JAMA Cardiol. 2016;1:831–841. - PMC - PubMed
    1. Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: From inflammation to fibrosis. Circ Res. 2016;119:91–112. - PMC - PubMed
    1. Ismahil MA, Hamid T, Bansal SS, Patel B, Kingery JR, Prabhu SD. Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: Critical importance of the cardiosplenic axis. Circ Res. 2014;114:266–282. - PMC - PubMed
    1. Sager HB, Hulsmans M, Lavine KJ, Moreira MB, Heidt T, Courties G, Sun Y, Iwamoto Y, Tricot B, Khan OF, Dahlman JE, Borodovsky A, Fitzgerald K, Anderson DG, Weissleder R, Libby P, Swirski FK, Nahrendorf M. Proliferation and recruitment contribute to myocardial macrophage expansion in chronic heart failure. Circ Res. 2016;119:853–864. - PMC - PubMed
    1. Bansal SS, Ismahil MA, Goel M, Patel B, Hamid T, Rokosh G, Prabhu SD. Activated t lymphocytes are essential drivers of pathological remodeling in ischemic heart failure. Circ Heart Fail. 2017;10:e003688. - PMC - PubMed

Publication types

Substances